Ideal for: AR resistance, weekly blood draws for PSA
VCaP cells were derived from a vertebral metastatic growth of a prostrate carcinoma. It one of the most desirable prostate cancer cell lines for in vivo studies as it exhibits many of the characteristics of clinical prostate carcinoma. VCaP is a great model to study AR resistance as it expresses AR splice variants that have been shown to drive resistance to AR antagonists (1). Despite these advantages of the VCaP xenograft tumor model, due to the difficult and variable growth in mice between research groups (2), its value is not being applied in vivo. VCaP cells exhibit very poor take rates (<20%) and high growth-rate variability in mice. The take rate would result in the need to inoculate many more animals than the study requires, but even if that approach were taken the growth kinetics are such that an efficacy study could not take place. OncoRat demonstrates a 90%+ take rate and by 3 weeks post-inoculation, tumor growth permits efficacy studies. VCaP tumors surpass 13,0000 mm3 around 4-5 weeks post inoculation.
Enabling Case Study: VCaP tumor kinetics in the OncoRat
Drug efficacy in VCaP in OncoRat
2mm X 2mm X 2mm tumor pieces of NSCLC were subcutaneously transplanted into the right flank of OncoRat, N=3 for each passage. Length of days to maximum tumor volume is shortened with each passage, allowing for early enrollment and short study lengths in efficacy studies
- European Urology. 2018 Apr;73(4):572-582.
- Eskra, J. (2015) Culture methods for VCaP prostate cancer cells
OncoRat VCaP products & services
- Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
- OncoRats off-the-shelf for engraftment at the customers facility
VCaP tumor serum PSA in OncoRat
Blood was collected prior to inoculation and then weekly after inoculation. Serum was separated and assessed for PSA. Serum PSA is highly correlative with VCaP tumor growth in the OncoRat.
correlation coefficient, r = 0.98